Effect of pentoxifylline on endothelial dysfunction, oxidative stress and inflammatory markers in STEMI patients.
Asmaa SaeedMohamed Moustafa FaroukNagwa Ali SabriMohamed Ayman SalehMarwa Adel AhmedPublished in: Future science OA (2024)
Aim: ST-elevation myocardial infarction (STEMI) patients suffer higher mortality and adverse outcomes linked to endothelial dysfunction (ED). Methods: 43 patients were randomized to pentoxifylline (PTX) 400 mg thrice daily (n = 22) or placebo (n = 21). Soluble vascular cell adhesion molecule-1, malondialdehyde, interleukin-1 (IL-1), interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP) and tumor necrosis factor-α (TNF-α) were assessed at baseline and 2 months. Results: After 2 months, no significant difference was observed in markers' levels between the 2 groups. However, a within-group comparison revealed a statistically significant change in hs-CRP in the PTX group (10.057 (9.779-10.331) versus 9.721 (6.102-10.191)), p = 0.032. Conclusion: PTX for 2 months in STEMI patients was safe and well-tolerated but had no significant detectable effect on ED, oxidative stress or inflammatory markers. Clinical Trial Registration: NCT04367935 (ClinicalTrials.gov).
Keyphrases
- oxidative stress
- st elevation myocardial infarction
- end stage renal disease
- ejection fraction
- clinical trial
- newly diagnosed
- percutaneous coronary intervention
- emergency department
- prognostic factors
- rheumatoid arthritis
- type diabetes
- randomized controlled trial
- cardiovascular disease
- coronary artery disease
- dna damage
- patient reported outcomes
- double blind
- physical activity
- acute coronary syndrome
- cell adhesion
- atrial fibrillation
- diabetic rats